Ani Pharmaceuticals (ANIP) Other Operating Expenses (2010 - 2026)

Ani Pharmaceuticals has disclosed Other Operating Expenses across 16 years of filings, most recently posting $119.2 million for Q2 2026.

• In Q2 2026, Other Operating Expenses changed N/A year-over-year to $119.2 million; the TTM figure through Jun 2026 stood at $233.1 million (changed N/A YoY), while the FY2025 annual figure was -$382000.0, down 107.14% from the prior year.
• Other Operating Expenses came in at $119.2 million for Q2 2026 at Ani Pharmaceuticals, up from $114.3 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $119.2 million in Q2 2026 to a low of -$295000.0 in Q3 2025.
• Average Other Operating Expenses over 4 years is $48.0 million, with a median of $48.1 million recorded in 2022.
• The largest YoY upside for Other Operating Expenses was 672.32% in 2022 against a maximum downside of 60.35% in 2022.
• Over 4 years, Other Operating Expenses stood at $48.1 million in 2022, then slumped by 88.88% to $5.3 million in 2024, then slumped by 101.63% to -$87000.0 in 2025, then surged by 137083.91% to $119.2 million in 2026.
• Per Business Quant data, the three most recent Other Operating Expenses figures were $119.2 million in Q2 2026, $114.3 million in Q1 2026, and -$87000.0 in Q4 2025.